Importantly, they indicate that the pharmacological inhibition of TRPV4, which has been suggested for the treatment of several airway diseases (46–48), as well as of cyclophosphamide-induced cystitis (21), may lead to undesirably decreased defensive responses of the bladder against rather common bacterial infections. Here, TRPV4 is linked to cystitis.